Molecular Structure
News
Inspire Provides 2008 Financial Guidance
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today revenue and expense guidance for the full year of 2008.
Inspire expects to record aggregate revenue in the range of $62-$76 million and expects operating expenses to be in the range of $109-$129 million in 2008. Based on current operating plans, the Company expects its cash and investments would provide liquidity through 2009. The revenue range is based on projected sales from AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. The Company is withdrawing the guidance previously provided for AzaSite 2008 revenues.
Inspire will provide additional financial, operating and program details and assumptions when it reports fourth quarter 2007 financial results on February 26, 2008 and hosts its quarterly earnings conference call that day at 10:00 am ET.